{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:18:11Z","timestamp":1792153091086,"version":"4.4.0"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11,16]]},"DOI":"10.1093\/jnci\/dji372","type":"journal-article","created":{"date-parts":[[2005,11,15]],"date-time":"2005-11-15T16:37:56Z","timestamp":1132072676000},"page":"1652-1662","source":"Crossref","is-referenced-by-count":1099,"title":["Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study"],"prefix":"10.1093","volume":"97","author":[{"given":"Bernard","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Lawrence","family":"Wickerham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena S.","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Robidoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese B.","family":"Bevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen T.","family":"Kavanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Margolese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn D.","family":"Runowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie G.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wolmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,11,16]]},"reference":[{"key":"key\n\t\t\t\t20171012231946_BIB1","unstructured":"Furr BJ, Patterson JS, Richardson DN, Slater SR, Wakeling AE. Tamoxifen (review). In: Goldberg ME, editor. Pharmacological and biochemical properties of drug substances. Vol. 2. Washington (DC): American Pharmaceutical Association; 1979 . p. 355\u201399."},{"key":"key\n\t\t\t\t20171012231946_BIB2","unstructured":"Adam HK. Pharmacokinetic studies with Nolvadex. Rev Endocrine-Related Cancer1981 ; (9 Suppl) : 131 \u201343."},{"key":"key\n\t\t\t\t20171012231946_BIB3","doi-asserted-by":"crossref","unstructured":"Wakeling AE, Valcaccia B, Newboult E, Green LR. Non-steroidal antioestrogens\u2014receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem1984 ; 20 : 111 \u201320.","DOI":"10.1016\/0022-4731(84)90197-3"},{"key":"key\n\t\t\t\t20171012231946_BIB4","unstructured":"Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res1987 ; 47 : 4517 \u20139."},{"key":"key\n\t\t\t\t20171012231946_BIB5","doi-asserted-by":"crossref","unstructured":"Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet1987 ; 2 : 171 \u20135.","DOI":"10.1016\/S0140-6736(87)90762-8"},{"key":"key\n\t\t\t\t20171012231946_BIB6","doi-asserted-by":"crossref","unstructured":"Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med1989 ; 320 : 479 \u201384.","DOI":"10.1056\/NEJM198902233200802"},{"key":"key\n\t\t\t\t20171012231946_BIB7","doi-asserted-by":"crossref","unstructured":"CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer1988 ; 57 : 604 \u20137.","DOI":"10.1038\/bjc.1988.137"},{"key":"key\n\t\t\t\t20171012231946_BIB8","doi-asserted-by":"crossref","unstructured":"Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst1991 ; 83 : 1299 \u2013306.","DOI":"10.1093\/jnci\/83.18.1299"},{"key":"key\n\t\t\t\t20171012231946_BIB9","doi-asserted-by":"crossref","unstructured":"Fisher B, Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst1991 ; 83 : 1278 \u201380.","DOI":"10.1093\/jnci\/83.18.1278"},{"key":"key\n\t\t\t\t20171012231946_BIB10","doi-asserted-by":"crossref","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst1998 ; 90 : 1371 \u201388.","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"key\n\t\t\t\t20171012231946_BIB11","doi-asserted-by":"crossref","unstructured":"Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst1999 ; 91 : 1541 \u20138.","DOI":"10.1093\/jnci\/91.18.1541"},{"key":"key\n\t\t\t\t20171012231946_BIB12","doi-asserted-by":"crossref","unstructured":"Efron B. Forcing a sequential experiment to be balanced. Biometrika1971 ; 58 : 403 \u201317.","DOI":"10.1093\/biomet\/58.3.403"},{"key":"key\n\t\t\t\t20171012231946_BIB13","doi-asserted-by":"crossref","unstructured":"Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Controlled Clin Trials1984 ; 5 : 348 \u201361.","DOI":"10.1016\/S0197-2456(84)80014-8"},{"key":"key\n\t\t\t\t20171012231946_BIB14","doi-asserted-by":"crossref","unstructured":"Freedman L, Anderson G, Kipnis V, Prentice R, Wang CY, Rossouw J, et al. Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. Controlled Clin Trials1996 ; 17 : 509 \u201325.","DOI":"10.1016\/S0197-2456(96)00016-5"},{"key":"key\n\t\t\t\t20171012231946_BIB15","unstructured":"Rosner B. Fundamentals of biostatistics, 4th ed. Boston (MA): Duxbury; 1995 . p. 590\u20134."},{"key":"key\n\t\t\t\t20171012231946_BIB16","doi-asserted-by":"crossref","unstructured":"Korn EL, Dorey FJ. Applications of crude incidence curves. Stat Med1992 ; 11 : 813 \u201329.","DOI":"10.1002\/sim.4780110611"},{"key":"key\n\t\t\t\t20171012231946_BIB17","doi-asserted-by":"crossref","unstructured":"Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med1993 ; 12 : 737 \u201351.","DOI":"10.1002\/sim.4780120803"},{"key":"key\n\t\t\t\t20171012231946_BIB18","doi-asserted-by":"crossref","unstructured":"Fisher B, Costantino J. Highlights of the NSABP Breast Cancer Prevention Trial. Cancer Control1997 ; 4 : 78 \u201386.","DOI":"10.1177\/107327489700400111"},{"key":"key\n\t\t\t\t20171012231946_BIB19","doi-asserted-by":"crossref","unstructured":"Pritchard KI. Is tamoxifen effective in prevention of breast cancer? Lancet1998 ; 352 : 80 \u20131.","DOI":"10.1016\/S0140-6736(98)85002-2"},{"key":"key\n\t\t\t\t20171012231946_BIB20","doi-asserted-by":"crossref","unstructured":"Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet1998 ; 352 : 98 \u2013101.","DOI":"10.1016\/S0140-6736(98)85012-5"},{"key":"key\n\t\t\t\t20171012231946_BIB21","doi-asserted-by":"crossref","unstructured":"Powles T. Breast cancer chemoprevention\u2014Quo vadis? The Breast2001 ; 10 (suppl. 3): 58 \u201361.","DOI":"10.1016\/S0960-9776(16)30010-8"},{"key":"key\n\t\t\t\t20171012231946_BIB22","doi-asserted-by":"crossref","unstructured":"Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet2003 ; 361 : 296 \u2013300.","DOI":"10.1016\/S0140-6736(03)12342-2"},{"key":"key\n\t\t\t\t20171012231946_BIB23","doi-asserted-by":"crossref","unstructured":"Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet1998 ; 352 : 93 \u20137.","DOI":"10.1016\/S0140-6736(98)85011-3"},{"key":"key\n\t\t\t\t20171012231946_BIB24","doi-asserted-by":"crossref","unstructured":"IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet2002 ; 360 : 817 \u201324.","DOI":"10.1016\/S0140-6736(02)09962-2"},{"key":"key\n\t\t\t\t20171012231946_BIB25","unstructured":"IBIS-II (Prevention) Protocol: An international multi-centre study of anastrozole vs. placebo in postmenopausal women at increased risk of breast cancer. June 2002 . Available at: http:\/\/www.ncrn.org.uk\/portfolio\/data.asp?ID=848 . [Last accessed: October 24, 2005.]"},{"key":"key\n\t\t\t\t20171012231946_BIB26","doi-asserted-by":"crossref","unstructured":"Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet2004 ; 364 : 858 \u201368.","DOI":"10.1016\/S0140-6736(04)16981-X"},{"key":"key\n\t\t\t\t20171012231946_BIB27","doi-asserted-by":"crossref","unstructured":"Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis1984 ; 52 : 339 \u201346.","DOI":"10.1016\/0021-9150(84)90064-9"},{"key":"key\n\t\t\t\t20171012231946_BIB28","doi-asserted-by":"crossref","unstructured":"Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat1988 ; 12 : 307 \u201310.","DOI":"10.1007\/BF01811244"},{"key":"key\n\t\t\t\t20171012231946_BIB29","doi-asserted-by":"crossref","unstructured":"Bruning PF, Bonfrer JM, Hart AA, de Jong-Bakker M, Linders D, van Loon J, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer1988 ; 58 : 497 \u20139.","DOI":"10.1038\/bjc.1988.248"},{"key":"key\n\t\t\t\t20171012231946_BIB30","doi-asserted-by":"crossref","unstructured":"Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC. Carbone PP, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst1990 ; 82 : 1327 \u201332.","DOI":"10.1093\/jnci\/82.16.1327"},{"key":"key\n\t\t\t\t20171012231946_BIB31","doi-asserted-by":"crossref","unstructured":"Bagdade JD, Wolter J, Subbaiah PV, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab1990 ; 70 : 1132 \u20135.","DOI":"10.1210\/jcem-70-4-1132"},{"key":"key\n\t\t\t\t20171012231946_BIB32","doi-asserted-by":"crossref","unstructured":"Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst1993 ; 85 : 1398 \u2013406.","DOI":"10.1093\/jnci\/85.17.1398"},{"key":"key\n\t\t\t\t20171012231946_BIB33","doi-asserted-by":"crossref","unstructured":"McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomise trial. The Scottish Cancer Trials Breast Group. Br Med J1995 ; 311 : 977 \u201380.","DOI":"10.1136\/bmj.311.7011.977"},{"key":"key\n\t\t\t\t20171012231946_BIB34","doi-asserted-by":"crossref","unstructured":"Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst1997 ; 89 : 776 \u201382.","DOI":"10.1093\/jnci\/89.11.776"},{"key":"key\n\t\t\t\t20171012231946_BIB35","unstructured":"Nordenskjold B, Rosell J, Rutqvist LE, Malmstrom P, Bergh J, Bengtsson NO, et al. The Swedish Breast Cancer Group trial of two versus five years of adjuvant tamoxifen: reduced coronary heart disease death rate in the five year group. Ann Oncol2004 ; 15 (suppl 3). Abstr. 206O ."},{"key":"key\n\t\t\t\t20171012231946_BIB36","doi-asserted-by":"crossref","unstructured":"Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, et al. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol2001 ; 21 : 255 \u201361.","DOI":"10.1161\/01.ATV.21.2.255"},{"key":"key\n\t\t\t\t20171012231946_BIB37","unstructured":"MacMahon B. Epidemiologic studies on endometrial, gastrointestinal, and other cancers in humans. Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin Oncol1997 ; 24 : S1-122 \u201339."},{"key":"key\n\t\t\t\t20171012231946_BIB38","unstructured":"Creasman WT. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol1997 ; 24 : S1-140 \u201350."},{"key":"key\n\t\t\t\t20171012231946_BIB39","doi-asserted-by":"crossref","unstructured":"Magriples U, Naftolin F, Swartz PE. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol1993 ; 11 : 485 \u201390.","DOI":"10.1200\/JCO.1993.11.3.485"},{"key":"key\n\t\t\t\t20171012231946_BIB40","doi-asserted-by":"crossref","unstructured":"Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol2002 ; 20 : 2758 \u201360.","DOI":"10.1200\/JCO.2002.20.11.2758"},{"key":"key\n\t\t\t\t20171012231946_BIB41","doi-asserted-by":"crossref","unstructured":"Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology2004 ; 63 : 1230 \u20133.","DOI":"10.1212\/01.WNL.0000140491.54664.50"},{"key":"key\n\t\t\t\t20171012231946_BIB42","doi-asserted-by":"crossref","unstructured":"Geiger AM, Fischberg GM, Chen W, Bernstein L. Stroke risk and tamoxifen therapy for breast cancer. Eur J Cancer Inst2004 ; 2 : 15 \u20136.","DOI":"10.1093\/jnci\/djh285"},{"key":"key\n\t\t\t\t20171012231946_BIB43","doi-asserted-by":"crossref","unstructured":"Duggan C, Marriott K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol2003 ; 21 : 3588 \u201393.","DOI":"10.1200\/JCO.2003.10.111"},{"key":"key\n\t\t\t\t20171012231946_BIB44","doi-asserted-by":"crossref","unstructured":"Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol1998 ; 125 : 493 \u2013501.","DOI":"10.1016\/S0002-9394(99)80190-1"},{"key":"key\n\t\t\t\t20171012231946_BIB45","doi-asserted-by":"crossref","unstructured":"Gorin MB, Costantino JP, Kulacoglu DN, Demirci FY, Wickerham DL, Fisher B, et al. Is tamoxifen a risk factor for retinal vaso-occlusive disease? Retina2005 ; 25 : 523 \u20136.","DOI":"10.1097\/00006982-200506000-00023"},{"key":"key\n\t\t\t\t20171012231946_BIB46","doi-asserted-by":"crossref","unstructured":"Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen and cataracts: a null association. Breast Cancer Res Treat2004 ; 87 : 189 \u201396.","DOI":"10.1023\/B:BREA.0000041626.76694.85"},{"key":"key\n\t\t\t\t20171012231946_BIB47","doi-asserted-by":"crossref","unstructured":"Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst1999 ; 91 : 1829 \u201346.","DOI":"10.1093\/jnci\/91.21.1829"},{"key":"key\n\t\t\t\t20171012231946_BIB48","doi-asserted-by":"crossref","unstructured":"Taylor AL, Adams-Campbell LL, Wright JT Jr. Risk\/benefit assessment of tamoxifen to prevent breast cancer\u2014still a work in progress? J Natl Cancer Inst1999 ; 91 : 1792 \u20133.","DOI":"10.1093\/jnci\/91.21.1792"},{"key":"key\n\t\t\t\t20171012231946_BIB49","doi-asserted-by":"crossref","unstructured":"Powles TJ. Endocrine prevention of breast cancer. Eur J Cancer Supp2004 ; 2 : 15 \u20136.","DOI":"10.1016\/j.ejcsup.2004.08.001"},{"key":"key\n\t\t\t\t20171012231946_BIB50","doi-asserted-by":"crossref","unstructured":"Cuzick J. Side effect with tamoxifen and solutions with aromatase inhibiters. Eur J Cancer Supp2004 ; 2 : 33 \u20134.","DOI":"10.1016\/j.ejcsup.2004.08.009"},{"key":"key\n\t\t\t\t20171012231946_BIB51","doi-asserted-by":"crossref","unstructured":"Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol2004 ; 22 : 4951 \u20137.","DOI":"10.1200\/JCO.2004.05.192"},{"key":"key\n\t\t\t\t20171012231946_BIB52","doi-asserted-by":"crossref","unstructured":"Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer2004 ; 100 : 1800 \u20136.","DOI":"10.1002\/cncr.20205"},{"key":"key\n\t\t\t\t20171012231946_BIB53","doi-asserted-by":"crossref","unstructured":"Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol2001 ; 8 : 580 \u20135.","DOI":"10.1007\/s10434-001-0580-9"},{"key":"key\n\t\t\t\t20171012231946_BIB54","unstructured":"Anderson BO, Rinn K, Georgian-Smith D, Lawton T, Li CI, Moe RE. Lobular carcinoma in situ. In: Silverstein MJ, Recht A, Lagios M, editors. Ductal carcinoma in situ of the breast, 2nd ed. New York (NY): Lippincott, Williams & Wilkins; 2002 . p. 615\u201334."},{"key":"key\n\t\t\t\t20171012231946_BIB55","doi-asserted-by":"crossref","unstructured":"Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol2001 ; 28 : 400 \u201318.","DOI":"10.1016\/S0093-7754(01)90133-2"},{"key":"key\n\t\t\t\t20171012231946_BIB56","doi-asserted-by":"crossref","unstructured":"Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer prevention. J Natl Cancer Inst2003 ; 95 : 526 \u201332.","DOI":"10.1093\/jnci\/95.7.526"},{"key":"key\n\t\t\t\t20171012231946_BIB57","doi-asserted-by":"crossref","unstructured":"Fisher B. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial: a reflective commentary. J Clin Oncol1999 ; 17 : 1632 \u20139.","DOI":"10.1200\/JCO.1999.17.5.1632"},{"key":"key\n\t\t\t\t20171012231946_BIB58","doi-asserted-by":"crossref","unstructured":"Dunn BK, Ford LG. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J2001 ; 7 : 144 \u201357.","DOI":"10.1046\/j.1524-4741.2001.007003144.x"},{"key":"key\n\t\t\t\t20171012231946_BIB59","doi-asserted-by":"crossref","unstructured":"Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA1999 ; 281 : 2189 \u201397.","DOI":"10.1001\/jama.281.23.2189"},{"key":"key\n\t\t\t\t20171012231946_BIB60","unstructured":"Goss PE. Targeting estrogen synthesis: a rational approach to preventing breast cancer. Cancer Prevention: New York-Presbyterian Cancer Centers Prevention Newsletter, Spring 2004 , Issue 3. Available at: http:\/\/www.nypcancerprevention.com\/issue\/3\/professional\/iss_ins.html ."},{"key":"key\n\t\t\t\t20171012231946_BIB61","doi-asserted-by":"crossref","unstructured":"The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet2002 ; 359 : 2131 \u20139.","DOI":"10.1016\/S0140-6736(02)09088-8"},{"key":"key\n\t\t\t\t20171012231946_BIB62","doi-asserted-by":"crossref","unstructured":"Love RR, Hutson PR, Havighurst TC, Cleary JF. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. Clin Cancer Res2005 ; 11 : 1500 \u20133.","DOI":"10.1158\/1078-0432.CCR-04-1610"},{"key":"key\n\t\t\t\t20171012231946_BIB63","doi-asserted-by":"crossref","unstructured":"Carpenter R, Miller WR. Role of aromatase inhibitors in breast cancer. Br J Cancer2005 ; 93 (Suppl 1): S1 \u20135.","DOI":"10.1038\/sj.bjc.6602688"},{"key":"key\n\t\t\t\t20171012231946_BIB64","doi-asserted-by":"crossref","unstructured":"Mouridsen HT, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer2005 ; 41 : 1678 \u201389.","DOI":"10.1016\/j.ejca.2004.10.020"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/97\/22\/1652\/7686828\/dji372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T19:51:07Z","timestamp":1586548267000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jnci\/article\/97\/22\/1652\/2521468\/Tamoxifen-for-the-Prevention-of-Breast-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,16]]},"references-count":64,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2005,11,16]]},"published-print":{"date-parts":[[2005,11,16]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/dji372","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,11,16]]},"published":{"date-parts":[[2005,11,16]]}}}